Please login to the form below

Not currently logged in
Email:
Password:

BACE1 inhibitor

This page shows the latest BACE1 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Biogen and Eisai drop Alzheimer’s drug elenbecestat

Biogen and Eisai drop Alzheimer’s drug elenbecestat

The failure of elenbecestat comes on the heels of Amgen and Novartis also  abandoning phase 2/3 studies of BACE1 inhibitor CNP520 (umibecestat) after some participants taking the drug saw their ... The sadly predictable pattern of the BACE inhibitor

Latest news

  • Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms

    Latest BACE inhibitor to run into trouble. Amgen, Novartis and Banner Alzheimer's Institute are to halt trials of their BACE1 inhibitor CNP520 (umibecestat) after some participants taking the drug saw ... The loss of CNP520 leaves just one major BACE

  • Eisai to tackle dementia in new US research facility Eisai to tackle dementia in new US research facility

    The area could very well be a gamble for the Japanese group as rivals AstraZeneca and Eli Lilly - who partnered up to look into BACE1 inhibitor candidates in Alzheimer’s - dropped ... Merck &Co has also seen failure with its BACE1 inhibitor verubecestat

  • Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

    The demise of the BACE1 inhibitor – also known as AZD3293/LY3314814 – adds to the litany of failures among drugs intended to treat Alzheimer’s, and specifically those trying to slow down ... A few weeks ago, Merck &Co abandoned its BACE1 inhibitor

  • Another Alzheimer's bust as Merck & Co stops verubecestat study Another Alzheimer's bust as Merck & Co stops verubecestat study

    Late-stage BACE1 failure could be an ominous signal for Eli Lilly/AZ and Biogen/Eisai. ... Merck &Co has abandoned the phase III trial of its BACE1 inhibitor verubecestat in Alzheimer’s in what could be an ominous signal for Eli Lilly/AstraZeneca and

  • Alzheimer's disease pipeline takes multiple hits Alzheimer's disease pipeline takes multiple hits

    MK 8931 (Merck &Co.) is a potential first-in-class, potent Aß precursor protein cleaving enzyme (BACE1) inhibitor. ... LY 2886721 (Lilly) is another BACE1 inhibitor that was in phase I/II development in the US, Japan and some EU countries, but the phase

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Interview: Mike Hutton, Lilly Interview: Mike Hutton, Lilly

    Lilly has not been immune from such difficulties. Its BACE1 inhibitor LY 2886721 and amyloid-beta treatment semagacestat also failed, the latter in a large phase III clinical trial.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics